Fortis Hospitals joins hands with RNTCP & ICMR for a TB free India

IMT News Desk
IMT News Desk
· 2 min read

Fortis Hospitals, Bangalore in association with Revised National Tuberculosis Control Programme (RNTCP) and Indian Council of Medical Research (ICMR) conducted ‘Tuberculosis Symposium’ with an aim to support government’s vision for a TB Free India. The symposium focussed on various aspects of Tuberculosis and the ways to eradicate it followed by a panel discussion and Q&A.

Along with senior doctors from Fortis Hospitals, various other doctors from National Tuberculosis Institute, ESIMC, and members of State TB Cell took part in the conference. The panel discussed on the Global & Indian Scenario, Diagnosis of TB, EPTB( Extra Pulmonary Tuberculosis), Treatment of TB, Role of Private Sector in Elimination of TB, Programmatic Management of Drug Resistant TB  during the symposium.

According to the World Health Organisation, India reported the world’s highest number of TB cases, of which at least half are treated in the private sector and their diagnoses and treatment are not noted in government records. A recent study revealed that there is an increase in active TB cases, with Karnataka reporting 68,000 cases last year.

Dr Shripad Patil, Director, ICMR-NGIL&OMD, Agra said, TB Free India campaign aims to ensure access to accurate diagnosis, affordable treatment and support to each TB patient. Kill the Killer.”

Dr Shalini Joshi, Senior Consultant , Internal Medicine Fortis Hospital, Bannerghatta Road said, “ The symposium brought all the private and public stakeholders at one platform to help each other work towards the same goal. We are optimistic that through our joint efforts, we will be able to provide our best to the patients.”

In an attempt to eliminate tuberculosis in India, Union Budget 2018 allocated Rs 600 crores for nutritional support to TB patients in India. This allocation, with an addition to Rs 1200cr set aside as patient social and nutritional support under national strategic plan for tuberculosis budget (2017-2020) is said to decrease the fall-out of patients from treatment due to lack of nutritional support.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk